These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Response to pneumococcal conjugate and polysaccharide vaccination in children with rheumatic disease. Jensen L; Christensen AE; Nielsen S; Pedersen FK; Rosthøj S; Jørgensen CS; Poulsen A Scand J Immunol; 2022 Feb; 95(2):e13118. PubMed ID: 34768311 [TBL] [Abstract][Full Text] [Related]
28. Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. Lee D; Jordan AI; Menges MA; Lazaryan A; Nishihori T; Gaballa SR; Shah BD; Pinilla-Ibarz J; Baluch A; Klinkova OV; Chavez JC; Jain MD; Locke FL Transplant Cell Ther; 2023 Apr; 29(4):277.e1-277.e9. PubMed ID: 35970303 [TBL] [Abstract][Full Text] [Related]
29. Pneumococcal 13-valent conjugate vaccine administration after inferior response to pneumococcal vaccine. Gupta R; Wong CS; Fonacier L Allergy Asthma Proc; 2017 Sep; 38(5):365-369. PubMed ID: 28814356 [TBL] [Abstract][Full Text] [Related]
30. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up. Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715 [No Abstract] [Full Text] [Related]
31. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study. Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160 [TBL] [Abstract][Full Text] [Related]
32. Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney transplant recipients. Oesterreich S; Lindemann M; Goldblatt D; Horn PA; Wilde B; Witzke O Vaccine; 2020 Apr; 38(17):3339-3350. PubMed ID: 32178906 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan. Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA; Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524 [TBL] [Abstract][Full Text] [Related]
34. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years. Schwarz TF; Schmoele-Thoma B Vaccine; 2013 Jan; 31(2):291-4. PubMed ID: 23123107 [TBL] [Abstract][Full Text] [Related]
35. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants. Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049 [TBL] [Abstract][Full Text] [Related]
36. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults. Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932 [TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781 [TBL] [Abstract][Full Text] [Related]
38. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Sinisalo M; Vilpo J; Itälä M; Väkeväinen M; Taurio J; Aittoniemi J Vaccine; 2007 Dec; 26(1):82-7. PubMed ID: 18053620 [TBL] [Abstract][Full Text] [Related]
39. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592 [TBL] [Abstract][Full Text] [Related]
40. A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age. Chu K; Hu Y; Pan H; Wu J; Zhu D; Young MM; Luo L; Yi Z; Giardina PC; Gruber WC; Scott DA; Watson W Hum Vaccin Immunother; 2023 Aug; 19(2):2235926. PubMed ID: 37549923 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]